Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 3777 - Provider product page
- Provider
- Cell Signaling Technology, Inc
- Proper citation
- Cell Signaling Technology Cat#3777, RRID:AB_2096270
- Product name
- Phospho-EGF Receptor (Tyr1068) (D7A5) XP® Rabbit mAb
- Antibody type
- Monoclonal
- Reactivity
- Human, Mouse, Rat, Simian
- Host
- Rabbit
- Storage
- -20°C
Submitted references xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H, Nagano O
Cancer research 2013 Mar 15;73(6):1855-66
Cancer research 2013 Mar 15;73(6):1855-66
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA
Science translational medicine 2012 Feb 8;4(120):120ra17
Science translational medicine 2012 Feb 8;4(120):120ra17
No comments: Submit comment
Supportive validation
- Submitted by
- tatarskii@gmail.com
- Main image
- Experimental details
- A431 cells were seeded in DMEM with 10% FBS, transferred to serum-free medium for 16 hours, treated with 100 ng/ml EGF for 10 minutes, the fixed.
- Sample type
- A431 [ATCC] , humam epidermoid carcinoma
- Primary Ab dilution
- 1:800
- Conjugate
- Unconjugated
- Secondary Ab
- http://www.cellsignal.com/products/4412.html
- Secondary Ab dilution
- 1:1000
- Protocol
- Protocol
